HK Main-Board Listed Tianda Pharmaceuticals(00455.HK) , A Promising Outlook for Growth

HONG KONG, Jul 10, 2020 – (ACN Newswire) – With the successive introduction of the "Opinions on Facilitating the Inheritance, Innovation and Development of Traditional Chinese Medicine (TCM)" in certain provinces in mainland China and the "Regulations on Traditional Chinese Medicine" proposed by the Beijing municipality (Drafted Regulations on TCM for Public Opinions), the TCM industry has embarked on a rapid development. The value of some Hong Kong listed small and mid-cap companies are gradually unveiled. Here is an example, Tianda Pharmaceuticals Limited (00455.HK), which emphasizes on "the development of the Chinese medicine industry as the foundation, the development of innovative medicines and medical technologies and the development of quality medical and health care services". The company has been drawing the attention from the market recently.

Headquartered in Hong Kong, the company has sales and distribution centers in Shenzhen, China and Sydney, Australia, which are responsible for sales network expansion and branding in Hong Kong, China, Australia, and global markets. At present, the company's products include chemical products, biological drugs, Chinese patent medicines, herbal medicines, herbal decoction pieces, health care products and supplements, covering the treatment of cardiovascular diseases, pediatric diseases, influenza and respiratory diseases, anti-infectives, detoxification, oncology and other therapeutic areas. In addition, the company has also developed a series of health care products and supplements under the brand names of "Herb Valley" and "Tuokang".

Opportunities are hidden in crisis
With the recent pandemic raging across the world, except for masks, alcohol and other basic epidemic prevention items, the demand for related medicines has also increased significantly. For example, the Ribavirin, one of the Tianda Pharmaceuticals's products, has been popular since the pandemic. In particular, at the early stage of the outbreak, Tianda Pharmaceuticals raced against time and quickly collaborated with leading Chinese medicine experts to develop a TCM formulas series to combat the disease, namely "Anti-Epidemic Formula 1" (for prevention), "Anti-Epidemic Formula 2" (for remedy) and "Anti-Epidemic Formula 3" (for rehabilitation) , and launched anti-epidemic campaigns in Guangdong, Hong Kong and Macau, to provide complimentary TCM consultation and Anti-Epidemic Formula 1 to more than 1,000 individuals, which was well received by society. In April 2020. Anti-Epidemic Formula 1 was approved for entry into the Australian Register of Therapeutic Goods as a listed medicine. It is the first TCM product to be registered in a market outside of China with preventive effects against influenza and the coronavirus disease, representing a a big step forward for Tianda Pharmaceuticals' TCM internationalization strategy .

TCM Industry has promising prospects as policies continue to be favorable
"It is expected that China's TCM and health industry may exceed 3 trillion yuan by 2020, and the average compound annual growth rate will remain at 20%." — Mentioned in the white paper entitled "TCM in China" published by State Council Information Office of the People's Republic of China. Moreover, it is expected the TCM market size may reach 170.8 billion yuan by 2022 and exceed 200 billion yuan by 2024, with an average annual compound growth rate of 10%. In 2020, the TCM market is expected to reach 580.6 billion yuan with a compound growth rate of 8.2%. With the growing awareness of using TCM and the increase in the spending power of Chinese households, Tianda Pharmaceuticals seizes the opportunity to penetrate the whole TCM industry chain from three aspects, namely Chinese medicine services, Chinese herbal medicine and TCM AI. The company has also established the "Tianda Standard", which is more stringent than the national standard to guarantee its TCM quality, and launched TDMalls, a new style Chinese medicine clinic chain. TDMall is based in the Guangdong-Hong Kong-Macao Greater Bay Area and seek to expand nationwide and even globally in the future, striving to develop into a leading brand of Chinese medicine clinic chain. The company has already launched a flagship clinic in Zhuhai, Guangdong in May 2019 and another flagship clinic in Causeway Bay, Hong Kong in February 2020. In addition, unlike the first two, the Australian TDMall is in the pipeline and will be operated as a health care center to take advantage Australia's blessed comfortable and healthy environment. In the future, the TDMall will promote womb care, pain treatment and recuperation as its signature services. Through leveraging on Internet technology, big data, artificial intelligence and other innovative technologies, the company has created "Cloud TDMall" to realize online and offline integration of Chinese medicine services and provision of remote diagnosis and treatment and consultation services, which provides the public with quality, convenient and comprehensive TCM health services, and helps the company to further promote the heritage, innovation and development of TCM.

Business performance remains solid
The company's revenue for FY2020 was HK$492 million, presenting a year-on-year decrease of 6.7% as shown in the full-year results released for the year ended 31, March 2020, However, the profit for the year attributable to shareholders was approximately HK$3.14 million, increasing 18.3% compared to the same period last year. The decline in overall revenue was mainly due to the change in national medical insurance policies, which had a significant impact on the sales volume of Cerebroprotein Hydrolysate, products produced by a subsidiary of Tianda Pharmaceuticals -Yunnan Meng Sheng Pharmaceutical Co., Ltd (Meng Sheng Pharmaceutical). However, the impact on the profit for the year attributable to shareholders was mitigated by the fact that Tianda Pharmaceuticals only held 55% in Meng Sheng Pharmaceutical. In addition, sales revenue of the Company's wholly-owned subsidiary, namely Tianda Pharmaceuticals (Zhuhai) Limited, increased by 38.3% from approximately HK$177 million in FY2019 to approximately HK$246 million in the current financial year, mainly due to its main products, namely Tuoping (Valsartan capsules) and Tuoen (Ibuprofen suspension), having great sales performance and increasing by 67.8% and 31.8% respectively as compared to that for the FYE 2019. Profit contribution from Tianda Pharmaceuticals (Zhuhai) increased by 55.4% from approximately HK$16.9 million for the FYE 2019 to approximately HK$34.2 million for the current financial year, which not only fully offset the impact of the decline in performance of Meng Sheng Pharmaceutical, but also contributed to the increase in profit for the year attributable to shareholders. Chinese herb medicines, decoction pieces and TDMall business are expected to maintain growth in the future. Tianda Pharmaceutical (Zhuhai) Limited's new research and development (R&D) and production base in Jinwan District, Zhuhai, China is expected to be ready for production in 2021 when the production capacity will be further enhanced, product variety will increase, economies of scale will maximize returns, hence proving sustained development dynamics.

Tianda Pharmaceuticals attaches importance to product R&D, and develops a wide range of products including classical TCM compound prescription, cosmetics and food products using the Cerebroprotein extraction process, and traditional Chinese medicine products such as herbal tea bag, herbal soup pack, Chinese herb syrup, health products of medicine and food with the same source, and series of mask products, etc. In response to the changes in health care reform policies, Tianda Pharmaceuticals makes every effort to consolidate and expand its generic medicine business and promote the growth of its innovative medicine business by means of diversifying sales channels, further exploring domestic and overseas markets, strengthening R&D and entering into business collaboration. At the same time, it follows national policy closely by developing TCM business with a focus on building a new clinic chain – TDMall.

Tianda Pharmaceuticals strives to build diversified channels for investors to interact with the company, thus maintaining close interaction with shareholders and investors, and promoting awareness of the capital market. The company is debt free and has been paying a steady dividend. The Board of Directors has recommended the dividend of 0.13 HK cents per share. It is believed that Tianda Pharmaceuticals will continue to drive business value to reward its shareholders in the future.


Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Avance Clinical Wins Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award

Adelaide, AUS, Jul 9, 2020 – (ACN Newswire) – The leading Australian CRO for biotechs, Avance Clinical, accepted the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award at a global virtual awards ceremony overnight. This is the first Frost & Sullivan award for the company which has seen rapid growth in the APAC region over the past year.



Avance Clinical CEO Yvonne Lungershausen



According to Frost & Sullivan:

"The Frost & Sullivan Best Practices Awards have honoured best-in-class companies that have demonstrated excellence in their respective industries. Award recipients were identified based on in-depth interviews, analysis, and extensive secondary research conducted by Frost & Sullivan analysts and companies are typically studied on their revenues, market share, capabilities, and overall contribution to the industry to identify best practices."

Avance Clinical CEO Yvonne Lungershausen:

Commending her team of more than 100 clinical trial specialists throughout Australia and New Zealand, "We have shown, with our repeat business rate greater than 75%, that our consistent sponsor focussed culture and nimble proactive approach wins every time. This has been recognised by the research team at Frost & Sullivan and the entire Avance Clinical team are very proud.

"Australia, which has successfully managed the COVID-19 crisis, is open for business for clinical trials. This award further reinforces to the biotech community that this is an early phase specialist destination where they can turn around delayed trials. Avance Clinical are experts in facilitating fast study startup with trials typically approved and initiated in under 6 weeks."

Avance Clinical is an Australian owned Contract Research Organisation that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years.

Avance specialises in supporting biotech companies with their early phase clinical trials, having conducted over 150 early phase (Phase 1 and 2) trials in the past 4 years, involving treatment of over 8,300 participants across 95 therapeutic indications.

According to Nidhi Jalali, Analyst Best Practices, Frost & Sullivan:

"Within Asia-Pacific's highly competitive CRO market, Avance Clinical stands out as a leader in early phase biotech clinical trials. Avance's reputation for high-quality clinical trial outcomes has attracted an impressive 74% repeat business rate, underscoring the company's position as a market leader.

Avance Clinical offers a highly responsive and proactive service for biotechs wanting rapid and innovative clinical trial solutions, with the highest level of data compliance. The company has grown quickly over the past year doubling staff numbers, with plans to further expand. Avance Clinical offers a real size match for biotechs, meaning better mission understandings and stronger customer service compared to the larger CROs."

In addition to the impressive COVID-19 management in Australia, a key factor in sponsor demand is the speed, access to high-quality sites and attractive cost of running trials in Australia including:
– The Australian Government financial rebate of up to 43.5% on clinical trial spend
– No IND required for clinical trials and streamlined regulatory processes
– Advanced medical, research and scientific community, leading investigators & KOLs, modern medical facilities

Australia's reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical trials.

Learn about running your next study with Avance Clinical: https://www.avancecro.com/.

About the Frost & Sullivan Awards

The Frost & Sullivan 2020 Best Practices Awards have honoured best-in-class companies that have demonstrated excellence in their respective industries. Award recipients were identified based on in-depth interviews, analysis, and extensive secondary research conducted by Frost & Sullivan analysts and companies are typically studied on their revenues, market share, capabilities, and overall contribution to the industry in order to identify best practices.

With a strong overall performance, Avance Clinical earns the 2020 Asia-Pacific CRO Market Leadership Award. We also recognize that your receipt of this award is the result of many individuals (employees, customers and investors) making daily choices to believe in the organization and contribute in a meaningful way to its future.

About Avance Clinical

Australia's Avance Clinical Pty Ltd has more than 20-years of experience and is now one of Australia's leading Contract Research Organisations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.

Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.

Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialised patient groups. Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. Telehealth pivot during COVID-19 pandemic – speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. An established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialised patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with long track records in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round taking advantage of Australia's counter-flu and allergy seasons

Media Contact:
media@avancecro.com
Chris Thompson


Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Research on Free-state Nicotine and Coronavirus Reveals Facts More Complex than we Thought

SHENZHEN, CHINA, Jul 9, 2020 – (ACN Newswire) – On February 9, Chinese academician Zhong Nanshan published a retrospective study on novel coronavirus cases in medRxiv, a medical preprint magazine. According to Zhong's paper "Clinical characteristics of the 2019 novel coronavirus infection in China" of 1099 new coronavirus patients, 927 were never smokers (85.4%), 21 are ex-smokers (1.9%) and 137 are current smokers (12.6%). The proportion of smokers in the Chinese population is 28.1%. These data seem to indicate that smokers are far less likely to be infected with the novel coronavirus than non-smokers.(1)

On April 22, France Inter reported that a research team from the Pitie-Salpetriere Hospital in Paris, led by Jean Pierre Changeux, a member of the French Academy of Sciences, launched research asking "Can nicotine protect the human body from invasion by the novel coronavirus?" The reason is that field surveys of new patients with novel coronavirus show a puzzling fact: compared with non-smokers, smokers are less likely to be infected.

The Paris researchers surveyed 350 hospitalized patients and 130 patients with mild symptoms who did not need to be hospitalized. Based on total population data from 2018, the researchers wanted to check whether these patients smoked more than other people of the same gender and age. The conclusion is that smokers are very rare among these patients."We found that only 5% of these patients are smokers. It's a low proportion. In general, the proportion of smokers is 80% less than other coronavirus-infected patients of the same gender and age," explained Zahir Amoura, a professor of internal medicine.

On the other hand, Jean Pierre Changeux speculated that nicotine may prevent the coronavirus from attaching to objects and human surfaces. Furthermore, it may prevent the coronavirus from invading cells. This may mean nicotine can inhibit the spread of virus and the novel coronavirus pneumonia.(2,3)

According to Israel's Jerusalem Post on June 7, Israeli scientists found that smoking can provide some protection against the novel coronavirus. The results are similar to those of researchers in China, France and Italy.

Since there were conflicting reports about the impact of smoking on the risk of contracting novel coronavirus, an Israeli team led by Dr Ariel extracted data from more than 3 million adult members of Clalit, Israel's largest health service center. Novel coronavirus pneumonia seems to be reduced by half in smokers, according to the result of their research.

Of the more than 3 million adults involved in the study, 114,545 were tested for the virus, of which only 4% were positive. The researchers matched people who tested positive to those who tested negative in a ratio of 1:4, taking into account as many variables as possible, such as age, gender and race. They found that among those who tested positive, smokers accounted for 9.8% and 19% of the total population.

Smoking seems to bring some benefits, with 11.7% of those who tested positive had a history of smoking, compared with 13.9% of the general population in the study. As a result, the study showed that people with a history of smoking had a 19% lower risk of contracting the virus.(4)

The study by Professor Zahir of the Pitie Salpetriere Hospital also showed that smokers are about half as likely to be infected as other people. Of the novel coronavirus pneumonia patients who visited the hospital from February 28th to April 9th, only 4.4% of inpatients and 5.3% of outpatients smoked daily, compared with 25.4% in the general population. The study also found that smokers were 80% less likely to have severe symptoms, leading researchers to suggest that the free-state nicotine in cigarettes binds to cell receptors to block the virus.

Similarly, a study of 28 papers by University College London showed that the number of smokers infected with coronavirus was "lower than expected"; A Chinese study also found that only 6.5% of 5,300 hospitalized patients with coronavirus were smokers; A study by the Centers for Disease Control and Prevention in the United States found that only 1.3% of the more than 7000 people who tested positive were smokers, the Daily Mail of Britain reported."Our results provide compelling evidence for the current association between smoking and an individual's risk of COVID-19 infection," the researchers wrote in the paper.(6)

"The potential benefit of free-state nicotine is that it can partly explain the exacerbation or adverse consequences of smokers hospitalized for coronavirus. It is because these patients will inevitably stop taking nicotine during hospitalization," Dr. Constantinos Fasalinos from the University of Siatica, Greece, wrote in his paper for internal medicine and emergency medicine.(7)

On February 2, experts in Shenzhen, China started relevant research on the IUOC, a heat-not-burn tobacco device, which attracted their attention. The nicotine produced by one cigarette heated by IUOC is the same as that produced by a lighted one, which is free-state nicotine. But the amount of nicotine released by a heat-not-burn cigarette is twice that of a lighted one, and it is almost pure nicotine aerosol. On July 1st, researchers found that more than 600 cigarette stores in Beijing were selling the IUOC device.

Media contact:
Shenzhen Yukan Technology Co., Ltd.
Rm 1110, West Tower, Nanshan Software Park,
No.10128, Shennan Road, Nantou Street, Nanshan District, Shenzhen, China
Facebook: https://www.facebook.com/iuoctech0
E-mail: info@iuoctech.com
Website: http://www.iuoctech.com/en

(1) https://www.medrxiv.org/content/10.1101/2020.02.06.20020974v1
(2) https://www.reuters.com/article/us-health-coronavirus-france-nicotine/french-scientists-to-test-theory-that-nicotine-combats-covid-19-idUSKCN2292O8
(3) https://www.qeios.com/read/FXGQSB (A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications)
(4) https://mp.weixin.qq.com/s/33Z_KVpxzK6jMWc2Gfo2tQ
(5) https://theguardian.com/world/2020/apr/22/french-study-suggests-smokers-at-lower-risk-of-getting-coronavirus
(6) https://www.dailymail.co.uk/news/article-8264635/More-proof-smokers-risk-catching-coronavirus-expert-admits-weird.html
(7) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210099/

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Research on Free-state Nicotine and Coronavirus Reveals Facts More Complex than we Thought

SHENZHEN, CHINA, Jul 7, 2020 – (ACN Newswire) – On February 9, Chinese academician Zhong Nanshan published a retrospective study on novel coronavirus cases in medRxiv, a medical preprint magazine. According to Zhong's paper "Clinical characteristics of the 2019 novel coronavirus infection in China" of 1099 new coronavirus patients, 927 were never smokers (85.4%), 21 are ex-smokers (1.9%) and 137 are current smokers (12.6%). The proportion of smokers in the Chinese population is 28.1%. These data seem to indicate that smokers are far less likely to be infected with the novel coronavirus than non-smokers.(1)

On April 22, France Inter reported that a research team from the Pitie-Salpetriere Hospital in Paris, led by Jean Pierre Changeux, a member of the French Academy of Sciences, launched research asking "Can nicotine protect the human body from invasion by the novel coronavirus?" The reason is that field surveys of new patients with novel coronavirus show a puzzling fact: compared with non-smokers, smokers are less likely to be infected.

The Paris researchers surveyed 350 hospitalized patients and 130 patients with mild symptoms who did not need to be hospitalized. Based on total population data from 2018, the researchers wanted to check whether these patients smoked more than other people of the same gender and age. The conclusion is that smokers are very rare among these patients."We found that only 5% of these patients are smokers. It's a low proportion. In general, the proportion of smokers is 80% less than other coronavirus-infected patients of the same gender and age," explained Zahir Amoura, a professor of internal medicine.

On the other hand, Jean Pierre Changeux speculated that nicotine may prevent the coronavirus from attaching to objects and human surfaces. Furthermore, it may prevent the coronavirus from invading cells. This may mean nicotine can inhibit the spread of virus and the novel coronavirus pneumonia.(2,3)

According to Israel's Jerusalem Post on June 7, Israeli scientists found that smoking can provide some protection against the novel coronavirus. The results are similar to those of researchers in China, France and Italy.

Since there were conflicting reports about the impact of smoking on the risk of contracting novel coronavirus, an Israeli team led by Dr Ariel extracted data from more than 3 million adult members of Clalit, Israel's largest health service center. Novel coronavirus pneumonia seems to be reduced by half in smokers, according to the result of their research.

Of the more than 3 million adults involved in the study, 114,545 were tested for the virus, of which only 4% were positive. The researchers matched people who tested positive to those who tested negative in a ratio of 1:4, taking into account as many variables as possible, such as age, gender and race. They found that among those who tested positive, smokers accounted for 9.8% and 19% of the total population.

Smoking seems to bring some benefits, with 11.7% of those who tested positive had a history of smoking, compared with 13.9% of the general population in the study. As a result, the study showed that people with a history of smoking had a 19% lower risk of contracting the virus.(4)

The study by Professor Zahir of the Pitie Salpetriere Hospital also showed that smokers are about half as likely to be infected as other people. Of the novel coronavirus pneumonia patients who visited the hospital from February 28th to April 9th, only 4.4% of inpatients and 5.3% of outpatients smoked daily, compared with 25.4% in the general population. The study also found that smokers were 80% less likely to have severe symptoms, leading researchers to suggest that the free-state nicotine in cigarettes binds to cell receptors to block the virus.

Similarly, a study of 28 papers by University College London showed that the number of smokers infected with coronavirus was "lower than expected"; A Chinese study also found that only 6.5% of 5,300 hospitalized patients with coronavirus were smokers; A study by the Centers for Disease Control and Prevention in the United States found that only 1.3% of the more than 7000 people who tested positive were smokers, the Daily Mail of Britain reported."Our results provide compelling evidence for the current association between smoking and an individual's risk of COVID-19 infection," the researchers wrote in the paper.(6)

"The potential benefit of free-state nicotine is that it can partly explain the exacerbation or adverse consequences of smokers hospitalized for coronavirus. It is because these patients will inevitably stop taking nicotine during hospitalization," Dr. Constantinos Fasalinos from the University of Siatica, Greece, wrote in his paper for internal medicine and emergency medicine.(7)

On February 2, experts in Shenzhen, China started relevant research on the IUOC, a heat-not-burn tobacco device, which attracted their attention. The nicotine produced by one cigarette heated by IUOC is the same as that produced by a lighted one, which is free-state nicotine. But the amount of nicotine released by a heat-not-burn cigarette is twice that of a lighted one, and it is almost pure nicotine aerosol. On July 1st, researchers found that more than 600 cigarette stores in Beijing were selling the IUOC device.

Media contact:
Shenzhen Yukan Technology Co., Ltd.
Rm 1110, West Tower, Nanshan Software Park,
No.10128, Shennan Road, Nantou Street, Nanshan District, Shenzhen, China
Facebook: https://www.facebook.com/iuoctech0
E-mail: info@iuoctech.com
Website: http://www.iuoctech.com/en

(1) https://www.medrxiv.org/content/10.1101/2020.02.06.20020974v1
(2) https://www.reuters.com/article/us-health-coronavirus-france-nicotine/french-scientists-to-test-theory-that-nicotine-combats-covid-19-idUSKCN2292O8
(3) https://www.qeios.com/read/FXGQSB (A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications)
(4) https://mp.weixin.qq.com/s/33Z_KVpxzK6jMWc2Gfo2tQ
(5) https://theguardian.com/world/2020/apr/22/french-study-suggests-smokers-at-lower-risk-of-getting-coronavirus
(6) https://www.dailymail.co.uk/news/article-8264635/More-proof-smokers-risk-catching-coronavirus-expert-admits-weird.html
(7) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210099/


Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Favored by Capital Market Again, MicroPort’s CRM Business Brings in New Investor

HONG KONG, Jul 6, 2020 – (ACN Newswire) – Thanks to capital market's growing expectation for the aging population and accelerated substitution of imported medical devices, China's medical devices industry has entered a golden age of rapid development. Hong Kong-listed medical devices company, MicroPort Scientific Corporation ("MicroPort",stock code: 00853) – which has positioned in ten business segments including cardiovascular devices, orthopedics devices, and cardiac rhythm management business – was favored by the capital market in 2020 and obtained substantial attention from a lot of heavyweight strategic investors.

Following its announcement on July 2 in relation to completion of the placing of 65,958,000 new shares and raising over HK$1.5 billion at a price with the lowest discount among all primary placings of healthcare companies listed in Hong Kong in the last 5 years, MicroPort announced on 5 July that its subsidiary – MicroPort Cardiac Rhythm Management Limited ("MicroPort CRM"), which focuses on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders – has entered into definitive agreements in connection with its Series B financing with total investment proceeds US$105 million. With the investments, MicroPort CRM's post-money valuation reaches about US$400 million. Hillhouse Capital Group will lead the Series B investment and will invest US$50 million. Current MicroPort CRM investor, Yunfeng Capital will also participate with an additional investment of US$25 million. MicroPort will also invest USD$30 million through its wholly owned subsidiary. These investments fully demonstrated investors' confidence on the development of medical devices industry and MicroPort CRM business.

Originally acquired in April 2018, MicroPort CRM designs, develops, and markets solutions for the management of heart rhythm disorders, such as implantable pacemakers and defibrillators, as well as heart failure with cardiac resynchronization therapy (CRT), worldwide. Headquartered in Clamart (outside Paris) France, MicroPort CRM has dedicated R&D teams in Clamart (outside Paris) and Shanghai, and world class manufacturing facilities in France, Italy, the Dominican Republic and China. Currently MicroPort CRM employs approximately 950 employees globally.

For decades, MicroPort CRM has been at the forefront of innovation in the CRM industry and has implanted more than one million patients worldwide with its pacemakers and defibrillators. The company is known for its cutting-edge technology, small, long-lasting devices, and the most advanced therapeutic solutions. In 2015, MicroPort CRM launched the PLATINIUMTM family of implantable defibrillators, which has the longest service life of any implantable defibrillator on the market, reducing the risks associated to frequent replacements. In 2019, the company launched ENOTM, TEOTM and OTOTM, the world's smallest family of pacemakers, 1.5T and 3T MRI conditional. In the CRT field, the company innovated with the SonRTM sensor, the world's only contractility sensor for automatic optimization of cardiac resynchronization, which, in a landmark trial called RESPOND-CRT, revealed that SonRTM is associated with a 35% reduction in the risk of hospitalization for heart failure. MicroPort CRM continues to innovate in CRT by developing AXONETM, an ultra-thin 1.2 F (0.4 mm) left ventricular lead, which will enable MicroPort CRM to lead the industry in expanding CRT therapy options.

MicroPort CRM will soon launch a new family of pacemakers, ALIZEATM and BOREATM, featuring Bluetooth technology and wireless remote monitoring, and plans to launch a complete new line of defibrillator systems in 2021, including devices and leads, 1.5T and 3T MRI conditional. The market introduction of these products will provide an additional inflection point for the growth prospects of the CRM franchise.


Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Jacobson Pharma Announces FY2020 Annual Results

HONG KONG, Jun 30, 2020 – (ACN Newswire) – Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced its annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2020 (the "FY2020" or the "Reporting Period").

Resilient Performance under Distressed Economy
Amidst the overwhelming business challenges from the distressed economy in Hong Kong, the Group delivered a solid performance by posting a modest 6.3% year-on-year growth bringing its total revenue to HK$1,571.5 million (FY2019: HK$1,478.1 million (restated)). Gross profit grew by 2.3% to HK$690.0 million (FY2019: HK$674.7 million (restated)), while profit attributable to shareholders of the Company softened by 13.9% to HK$215.6 million (FY2019: HK$250.6 million (restated)) mainly due to the one-off revaluation gains recognised in the previous year, along with the increase in investments and operating expenses in setting up a regional management structure plus one-off professional expenses in preparing for the separation of the Group's consumer health business.

The Board recommends payment of a final dividend of HK2.5 cents per share (FY2019: HK3.0 cents per share). Combined with the interim dividend of HK2.0 cents per share, the full-year dividend for FY2020 remains the same as last year at HK4.5 cents per share. The Group's EBITDA (Adjusted) increased by 3.9% to HK$476.2 million, representing its strong capability of generating cash inflows.

Strong Market Position in Generics
Carrying a strong portfolio of generic drugs and a leadership position in a number of therapeutic categories in Hong Kong, the generic drugs business of the Group registered a positive growth of 3.6% in sales revenue in FY2020, amounting to HK$1,298.7 million (FY2019: HK$1,253.0 million), despite a decline in in-person consultation visits to medical clinics due to Covid-19 pandemic in the last quarter of the financial year.

The Group's offerings in certain therapeutic classes demonstrated strong growth, with oral anti-diabetic and anti-ulcerative products registered a robust growth of 42.3% and 34.1% respectively, which was attributed to an increased usage of these essential medicines in chronic disease management. In addition, the cardiovascular products achieved a sales growth of 28.4%, whilst the non-steroidal anti-inflammatory drugs (NSAIDs) also grew by 28.7% due to an expanded market position in the public hospital sector.

The Group launched 19 new products during the reporting period, including some difficult-to-make products such as Diltiazem Controlled Release Tablets, Dihydrocodeine Tablets, Perindopril Tablets, Atomoxetine Capsules, Mesalazine Enteric Coated Tablets 500mg and Finasteride Tablets. Besides, over 27 regulatory filings were submitted for new drug registration by the Group.

Tapping New Market Potentials with High Value-added Offerings
In supplementing its R&D pipeline and portfolio offerings, the Group has signed in-license agreements with a host of multi-national companies for a total of 79 specialised drugs covering several therapeutic classes including cardiovascular, central nervous system, infectious diseases, oncology, gastrointestinal, and ophthalmology, as well as a medical device for RSV (Respiratory Syncytial Virus) and Influenza rapid diagnostics test kit. Among them, 23 items are eligible for tender bidding in the coming years, and 22 items have been launched in Hong Kong.

Notable Growth in Proprietary Medicines with Newly Acquired Business
Albeit the negative sentiments prevailing in the retail sector, the Group's proprietary medicines business during the reporting period still registered a double-digit growth. With the incorporation of its newly acquired proprietary Chinese medicine business, sales revenue of the Group's proprietary medicine segment posted a 21.2% growth to HK$272.8 million (FY2019: HK$225.1 million).

Despite the economic distress, resilient performance has been demonstrated by proprietary brands such as Ho Chai Kung, a well-recognised heritage brand in the analgesics category, which delivered a notable growth of 10.8% over the same period of last year. Shiling Oil, a medicated oil brand of the Group, also presented a growth of 8.4% in overseas markets building on its strong tradition and recognition backed by persistent market development efforts.

Regional Expansion Strategy with China Focus
On the front of business development driven by its regional strategy, the Group has been actively forging strategic collaborations with multinational partners that cover in-licensing and representation of reputable branded products in Greater China and Asia regions.

The Group has respectively entered an exclusive distribution agreement with Vemedia for marketing and distribution of the renowned medicated foot care brand Excilor in Mainland China and a joint venture agreement with Kin Fung Weisen-U Company Limited to distribute and sell certain of its products – including the well-recognised gastrointestinal OTC drug "Weisen-U" and the popular nasal spray brand "Flucur Nebuliser" – to new markets in the Asia Pacific region, as well as to explore and develop product extensions in broadening the proprietary medicine platform of the Group.

In the consumer nutrition arena, the Group has entered an in-license agreement with Smartfish from Norway in a strategic collaboration to launch its patented and clinically substantiated high dose Omega-3 health and sports nutrition drinks in Greater China.

Tapping into the potential of the fast-growing cross-border e-commerce in China, the Group has developed its self-operating flagship store in a leading cross-border e-commerce platform in China in collaboration with key strategic partners to fully exploit the demand for proprietary medicines and consumer healthcare products among Mainland consumers, especially in Southern China and the Greater Bay Area.

Consumer Health Spin-off to Facilitate Expansion
By leveraging its regional commercial operations and focusing its efforts to tap into the burgeoning consumer healthcare market, the Group is also actively pursuing a spin-off of its branded consumer health business comprised of a strategically selected portfolio of branded medicines, proprietary Chinese medicines, and health and wellness products including health supplements, personal care products and diagnostic kits.

The potential spin-off is expected to facilitate the expansion of the consumer health business under a separate nimble platform from the generic drug business of the Group and groundworks have been undertaken to prepare for the spin-off plan.

Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, said, "We will continue to strive for business excellence across all divisions as we pursue our goal of creating two separate and nimble platforms through a spin-off of our branded consumer health business from the Group. This separation initiative serves as a catalyst to reset capabilities and cost base, and helps deliver a value-creation opportunity for both businesses. It is also a significant step forward in terms of shaping Jacobson into a company comprising two enterprises, one being intently focused on its generic drugs business whilst the other is principally focused on consumer health products."

Mr. Sum added, "The dynamic and challenging environment requires us to continually assess our market position to ensure that our business remains relevant and strategically well-aligned. Looking ahead, we remain confident that by building on our reputation, strong R&D pipeline and network resources of the Group, we are well positioned to deliver a sustainable growth and returns to our shareholders in the long term."

About Jacobson Pharma Corporation Limited (Stock Code: 2633)
Jacobson Pharma is a leading generic drug company in Hong Kong. The Group also carries a portfolio of proprietary brands, notably being Po Chai Pills, Ho Chai Kung TjiThung San, Contractubex Scar Gel, Flying Eagle Woodlok Oil, Tong Tai Chung Woodlok Oil, Doan's Ointment, Saplingtan, Shiling Oil and Col-gan Tablet, which have been widely recognised by the market. In the strategic expansion of its branded healthcare business platform, the Group has introduced health and wellness brands and products such as Dr. FreemanFlu/RSV Combo, SmartfishHealth Nutrition Products, Dr.Freeman Infection Control Product Series and Dr Freeman COVID-19 Rapid Test Kit, among other reputable brands represented in overseas markets such as Excilor and Weisen-U.

The Group aims at the continued strategic enrichment of both of its generic drug and branded healthcare portfolios through the addition of high value-added products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan, Singapore and Cambodia forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com

For media enquiries, please contact:
Strategic Financial Relations Limited
Vicky Lee Tel: (852) 2864 4834 Email: vicky.lee@sprg.com.hk
Stephanie Liu Tel: (852) 2864 4852 Email: stephanie.liu@sprg.com.hk
Rachel Ko Tel: (852) 2864 4806 Email:rachel.ko@sprg.com.hk
Fax: (852) 2527 1196


Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Captiva Verde Land Corp Announces Solargram Farms Corporation Receives Health Canada Standard Cultivation Cannabis License for Renauds Mills, New Brunswick

Coquitlam, British Columbia, Jun 30, 2020 – (ACN Newswire) – Captiva Verde Land Corp. (CSE: PWR) (the "Company") is extremely pleased to announce that Solargram Farms Corporation ("Solargram"), a Canadian controlled private corporation, having corporate offices in Moncton, NB has officially received its Standard Cultivation Cannabis License from Health Canada. The license was issued in accordance with the Canadian Cannabis Act and Cannabis Regulations. 100% of the Solargrams shares are held in an escrow account ready to be transferred to Captiva Verde in exchange for 35 Million Captiva shares subject to a tight pooling agreement, subject to Health Canada approving the application by all the Captiva Verde officers and directors to pass a security clearance and CSE approval.

Under this Health Canada License, Solargram is now authorized at its site location to conduct the activities listed below:

– From its indoor-area special purpose, state of the art Greenhouse facility: cultivation, propagating, testing, harvesting, and selling cannabis,
– From its custom designed, massive outdoor farm grow area: cultivation, propagation, and harvesting cannabis.

It has taken Solargram eighteen (18) months to have achieved this major milestone while recently completing final installation of its New Brunswick 5.6 million square feet grow infrastructure build out located in Renauds Mills, New Brunswick in anticipation of receiving its Standard Cannabis Cultivation License.

The CEO of Captiva Verde Jeff Ciachurski states: "With this exciting news release I declare my intention to purchase 500,000 additional shares of Captive Verde on the open market and as CEO of Greenbriar Capital Corp (which already owns 10.7 million shares of Captiva Verde) declares its intention to seek Toronto Venture Exchange approval to purchase an addition 3 million shares of Captiva Verde on the open market.

Renauds Mills Site Infrastructure Buildout Results

Over the last six months through the best winter and spring conditions in the area in over a decade, the extremely dedicated and focused Solargram team led by Len Wood, Executive Vice President Captiva Verde and Vice President Solargram Farms, and Marc LeBlanc, President Solargram Farms, have amazingly achieved:

– Installation of over 8,000 feet of security perimeter fencing over approximately 50 acres,
– Implementation of one of Canada's top robust, lowest-cost outdoor farm grown cannabis cultivation facilities having significant, highly cost efficient, infrastructure assets,
– Purchasing and integrating an approximate 130 land acres package together with an onsite six million gallon water holding pond as well as high capacity water wells to self-serve our planned cannabis outdoor grow farm,
– Purchasing, renovating, and repurposing three onsite buildings totalling over 36,000 square feet, allowing for vertically integrated seed-to-sale, onsite propagating mothers and clones, de-bucking, milling, drying, and extraction operation capabilities for 2020 and beyond. Outdoor farm cannabis crop planting now underway to produce an expected year one 10,000+ kg's of dried cannabis over 25 acres (1,100,000 square feet) with combination hoop house crop coverage including specific designed additional micro climate grow areas to achieve for increased crop protection and maximization of cannabis grow cultivation yield.
– Site infrastructure buildout was fully funded, completed on time, and was completed 65% under original capital budget. We remain completely debt free, and are now funded for our 2020 grow season.

Len Wood states, "Marc and I wish to congratulate all of our team members for their immense effort and dedication in aiding Solargram to achieve this amazing Health Canada licensing milestone. We have truly created an operation that is built for success based on sound business practices including fiscal responsibility as well as planned positive sustainable operating cash-flows, which is a real business. We wish to thank all of our loyal stakeholders that have continued to support our vision while understanding our mission to create a unique Canadian Licenced Producer cannabis market leader that will show and demonstrate the business model required to produce sustainable positive annual cash flow profits, while providing enhanced returns for our shareholders."

Captiva Verde is proud that the company has now positioned Solargram's world class team of experienced operators and growers with a financially debt-free, fully developed set of land assets, growing assets, buildings, proprietary IP and technological expertise to successfully run and operate significantly planned, vertically integrated, cannabis outdoor grow farm land acreages at a planned and budgeted ultra-low sub $0.25 production grow cost per gram. Outdoor grow is a major market disruptor and differentiator and this will allow Solargram to sell its planned high cannabinoid full spectrum cannabis oil products at prices that are significantly below its competitors cost of production as well as below black market pricing. Outdoor is a game changer and will allow our company to become an effective leader in this market.

Solargram has a five year planned outdoor farm grown production capacity in excess of 130 farm acres at the Renaud Mills New Brunswick outdoor grow site alone representing over 65,000 kg's of dried cannabis targeted for end product full spectrum cannabis oil (THC, THCV, CBD, CBG, CBD-THC) concentrate for export as well as for end product, best in class unique cannabis and edible products.

According to The Guardian less than 10% of Canada's current legal cannabis products are derived from outdoor operations. Sun grown outdoor plants have the lowest cost with consistent high yields and potency, providing consumers with an opportunity to choose from a selection of natural and healthier products than what the market currently offers. Publicly released results from three (3) Canadian outdoor licensed grow facilities in 2019 reported cash costs of between eight (8) cents to twenty-four (24) cents per gram. The new successful companies like Solargram, can provide both a superior product and a price point, inclusive of taxes, that is well below the black market rates, which the latter currently outperforms the legal market at a rate of more than three to one.

Solargram embraces the experiences of long time growing veterans, scientist and proven business leaders whose collective experience together, puts cannabis where its intention is most valued, to the trusted consumer. Cannabis is an evolutionary business within a revolutionary change of politics. The torch is being handed back to veteran growers, scientist and proven business leaders who understand the original intent of legalization, which is to have the lowest cost, first in class products available to everyone.

On Behalf of the Board of Directors
"Jeff Ciachurski"
Jeffrey Ciachurski
Chief Executive Officer and Director
Cell: (949) 903-5906
E-mail: westernwind@shaw.ca

Cautionary Note Regarding Forward Looking Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Hygeia Healthcare Successfully Listed on Main Board of SEHK, Further Strengthen Its Leading Market Position

HONG KONG, Jun 29, 2020 – (ACN Newswire) – The largest oncology healthcare group in China, Hygeia Healthcare Holdings Co., Limited ("Hygeia Healthcare" or the "Company", together with its subsidiaries, the "Group", stock code: 6078), is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") at 9:00 a.m. this morning. Hygeia Healthcare opened at HKD22.80 per share on the first trading day and the highest share price recorded throughout the day was HKD27.70 per share, an increase of 21.49%. The closing price was HKD26.00 per share, which was about 40.54% higher than the offer price; the trading volume was about 78.68 million shares, with a total turnover of approximately HKD1,913 million, and total market value amounted to HKD15.6 billion.





Mr. Fang Min, Chairman of the Board and Non-executive Director of Hygeia Healthcare Holdings Co., Limited, said, "Today marks an important milestone in Hygeia Healthcare's development. The official listing on the SEHK is a great recognition of our business strategy and philosophy, providing us enough momentum to further accelerate our development. At the same time, by stepping into the international capital market, it will be more conducive for us to expand diversified financing channels, strengthen our financial position and enhance the brand image of Hygeia Healthcare. We are honored to receive enthusiastic support from our investors. As an oncology-focused healthcare group, Hygeia Healthcare has always endeavored to make healthcare services more accessible and affordable, addressing unmet demand of oncology patients in China. Looking forward, we will expand our network of oncology-focused hospitals and radiotherapy centers to broaden our business scale and enlarge market share; upgrade our existing in-network hospitals to improve our service capacity and widen our service offering; continue to improve the quality of healthcare services provided by our in-network hospitals and further enhance our brand awareness; and further optimize the oncology healthcare service industry chain to continuously strengthen our leading edges and enhance our core competitiveness, striving to create great investment returns for our shareholders and investors."

Morgan Stanley Asia Limited and Haitong International Capital Limited are the Joint Sponsors. Morgan Stanley Asia Limited, Haitong International Securities Company Limited, and Huatai Financial Holdings (Hong Kong) Limited are the Joint Global Coordinators; Morgan Stanley Asia Limited (in relation to the Hong Kong Public Offering), Morgan Stanley & Co. International plc (in relation to the International Offering), Haitong International Securities Company Limited, and Huatai Financial Holdings (Hong Kong) Limited are the Joint Bookrunners and Joint Lead Managers.

About Hygeia Healthcare Holdings Co., Limited
Hygeia Healthcare Holdings Co., Limited (stock code: 6078), as an oncology-focused healthcare group, endeavors to make healthcare services more accessible and affordable, addressing the unmet demand of oncology patients in China. According to Frost & Sullivan, Hygeia Healthcare is the largest oncology healthcare group in China in terms of revenue generated from radiotherapy-related services in 2019 and number of radiotherapy equipment installed in in-network hospitals and radiotherapy centers as of December 31, 2019. Since the start of its business in 2009, Hygeia Healthcare has built a nationwide footprint of oncology-focused hospitals and radiotherapy centers through a combination of organic growth, strategic acquisitions, and cooperation with hospital partners.


Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance

SINGAPORE, Jun 24, 2020 – (ACN Newswire) – Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. has announced proven in vitro success with Equivir and 3F Biofragrance against COVID-19 in independent laboratory testing. Impact Biomedical and Global Research and Discovery Group Sciences (GRDG), in the advanced Biosafety Level 3 containment facilities of an independent laboratory, challenged the compounds with the SARS-CoV-2 virus. Equivir proved successful as a treatment, as well as a prophylactic protecting the cells from infection by the virus. Currently, there are no COVID-19 prophylactics.

3F Biofragrance proved successful as a surface disinfectant, killing the virus in concentrations as low as 1/5000 after 15 seconds. These in vitro results confirm the predictions of advanced computational molecular docking in which Equivir and Linebacker bind with a high affinity to the COVID-19 helicase and protease. Equivir and Linebacker also caused transformational change in the host ACE-2 receptor, interfering with the virus' ability to interact and infect the host cell. The binding affinity of components of 3F Biofragrance were also observed during molecular docking.

Equivir is designed and patented as a prophylactic to be deployed in a manner similar to a vitamin. It works by impeding virulence while also blocking multiple methods used by viruses to infect and replicate in host cells. Equivir treats and protects against diseases caused by not only SARS-CoV-2 but also other dangerous pathogens. Equivir has broad antiviral efficacy against multiple types of Influenza, Rhinovirus, Cholera, Ebola, and COVID-19.

Linebacker was created to shadow the Panacea Project, a US Defense Advanced Research Projects Agency (DARPA) program to provide novel, multi-target therapeutics for unmet physiological needs. Linebacker is under continuing research against COVID-19 as it showed efficacy against SARS and MERS in previous laboratory testing. Linebacker is a patented universal therapeutic medication with demonstrated effectiveness in neurological diseases including Parkinson's, many types of cancer, and multiple pathogens such as MRSA, E. coli, Cholera, A. baumannii, Influenza, SARS, MERS, Malaria, and Ebola.

3F Biofragrance was designed for the Open Air Defense Initiative, a strategy to protect large numbers of people where they gather such as containment areas, ports of entry, train stations, airports, convention centers, offices, schools, and hospitals. 3F Biofragrance technology also provides protection against mosquito-borne diseases such as Zika, Malaria and Dengue fever and is 10-fold more effective than DEET. 3F Antiviral Biofragrance is effective against E. coli, MRSA, Influenza, Rhinovirus, Tuberculosis, and COVID-19.

3F Biofragrance was developed in collaboration with Chemia Corporation (Chemia), world-renowned for the development of fragrances and flavors for personal, household, and industrial applications. The combination of GRDG's advanced scientific research and Chemia's expert formulation and global production infrastructure make this patent pending technology powerful and effective in protecting people from deadly pathogens and insects. "Chemia is proud to partner with GRDG to pioneer functional fragrances to not only enrich peoples' lives, but save them as well," said Thomas A. Meyer, Vice-President of Innovation and Sustainability at Chemia.

GRDG's Chief Scientific Advisor is Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention or CDC. Dr. Moore said, "GRDG's novel strategy of attacking diseases in multiple different ways is the future of effective pandemic response."

GRDG's Chief Strategy Advisor is Lieutenant Colonel William H. Lyerly Jr., retired Career Senior Executive/Scientific Professional from the U.S. Department of Homeland Security and retired U.S. Army Medical Service Corps Officer. Lieutenant Colonel Lyerly also served as a senior official in the U.S. Department of Health and Human Services, the U.S. Agency for International Development, and the U.S. Executive Office of the President (White House). Lieutenant Colonel Lyerly said, "The validation of these solutions demonstrates GRDG's skill in providing comprehensive solutions to global health threats."

Daryl Thompson, Director of Scientific Initiatives and founder of GRDG said, "I am happy to see that the 3F and Equivir biological countermeasures are performing as expected in independent efficacy testing. These positive results against the SARS-COV-2 virus now allow us to expeditiously move Equivir to clinical trials which we expect to be completed within the year. The 3F technology is ready for deployment in consumer products now."

Impact Biomedical's technology solutions have been developed in strategic partnership with GRDG. Mr. Chan Heng Fai. "I am greatly encouraged by the results and the team's contribution to this cause. We hope this will eventually prove to be beneficial for everyone, and we look forward to further exciting discoveries," said Mr. Chan.

GRDG is actively engaging with large global corporations to position the technologies for rapid integration into multiple distribution routes, to deploy these life-saving solutions worldwide. The intention in regards to the COVID-19 situation is to establish strong novel research data which can be further developed and licensed to a major pharmaceutical company for integration and eventual deployment as treatment for diseases. Shareholders and potential investors in SeD are advised to read this Press Release and any further announcements made by SeD carefully.

Shareholders and potential investors of SeD are advised to refrain from taking any action with respect to their securities in SeD which may be prejudicial to their interests, and to exercise caution when dealing in the securities of SeD. Shareholders and potential investors of SeD should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

About Singapore eDevelopment Limited
Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email contact@sed.com.sg.

About Impact BioMedical, Inc.
Impact BioMedical, Inc. ("Impact BioMedical") is a wholly-owned direct subsidiary of Global BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange.

Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDG Sciences, LLC. and Australian Exchange-listed Holista CollTech Limited, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno related diseases.

About GRDG Sciences, LLC.
GRDG Sciences, LLC is an advanced research team formed in Florida by natural products discovery drug research scientist, Daryl Thompson. For more information, please visit: http://www.globalrdg.com.


Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Launch of EIU report showing lack of integrated follow up care can increase risk of subsequent heart attack or stroke in APAC economies

HONG KONG, Jun 23, 2020 – (ACN Newswire) – Rehabilitation services designed to keep patients well and prevent their hospital readmission is key to reducing the incidence and cost of recurring (secondary) heart attacks or strokes (2). However, these services across the region remain underdeveloped (1).





This is according to a white paper "The cost of inaction: Secondary prevention of cardiovascular disease in Asia-Pacific", released today by leading public policy commentator The Economist Intelligence Unit (EIU), and sponsored by Amgen. (https://tinyurl.com/y8xwmu4w).

The report included a Scorecard which assessed the policy response to cardiovascular disease (CVD) across eight Asia-Pacific markets, including Australia, mainland China, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand. It follows the 2018 EIU report, "The cost of silence: Cardiovascular disease in Asia", which examined the prevalence and costs of the top four modifiable risk factors that contribute to CVD across the same eight markets.

An estimated 80% of CVD, including heart disease and stroke, is preventable (3]. For example, lowering
LDL-C ('bad' cholesterol) reduces cardiovascular events (4), yet patients in Asia-Pacific are routinely not meeting guideline-defined LDL-C goals (5-8), due to lack of medication adherence (5).

Due to the high risk of recurrence of heart attacks and stroke (9), the two deadliest forms of CVD (10), secondary prevention through quality follow up care once patients leave hospital, is important to help to minimize the CVD economic burden (11).

"Patients who have experienced a heart attack or stroke carry a 30% higher risk of another event over the ensuing four year (9). Furthermore, two in three stroke survivors experience disabilities, such as paralysis or loss of vision (12). As a result, survivors may be unable to work or study, and may require the support of family members. This can pull family caregivers away from employment, training or education. As such, CVD-related disability can disrupt households and threaten family stability (13)," said Mr. Vernon Kang, Chief Executive Officer, Singapore Heart Foundation. "CVD already accounts for approximately 18 million deaths each year worldwide (10). The findings from 'The cost of inaction: Secondary prevention of cardiovascular disease in Asia-Pacific' confirms more can be done to ensure patients are supported to comply with their treatment and rehabilitation needs, and to reduce their risk of secondary disease, for which they are at high risk (4,5,14)."

Key findings from the report include (1):
– Heart attacks are rising among younger people across the Asia-Pacific markets examined.
– Heart disease is costing the Asia-Pacific markets USD 46.3 billion (estimated across Australia, mainland China, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand).
– CVD policies do exist in some form in all economies studied, however there is substantial room for improvement.
– Policies on modifiable risk factors exist, but the success of translating these into legislation and action, along with measuring impact, remains to be defined.
– Only one market (Australia) has implemented a comprehensive secondary prevention of CVD public health awareness campaign.
– Clinical practice guidelines for CVD secondary prevention, heart attack and stroke, vary substantially across economies.
– Government audits are lacking. Only two study economies have any form of audit in place.
– Integrated primary care systems are still emerging in many Asian economies, and in many cases, patient uptake of services remains low.

"Empowering patients through education and awareness may help to overcome the various barriers to attendance at, and participation in, cardiac rehabilitation across the region. Cardiac rehabilitation involves multidisciplinary CVD management plans combining exercise, education and behaviour modification. Although they have been shown to significantly improve patient outcomes (15,16), the white paper revealed participation rates across Asia-Pacific were as low as 6% in some economies," Mr Kang said.

Commenting on the findings, Amgen Vice President and regional General Manager, Penny Wan, said now more than ever, avoiding re-hospitalization from Cardiovascular disease, was imperative. "In many countries, good emergency care stops people dying from a heart attack or stroke. However, these patients are at higher risk of having another attack, which is compounded by lack of follow-up care, making future events more difficult to manage."

"Amgen is committed to working as part of a coordinated, multi-stakeholder approach to shift healthcare models from 'Break It Fix It', to one that seeks to 'Predict and Prevent' to support patients and health care systems to become more resilient to health care shocks such as a pandemic," Ms. Wan said.

The Economist Intelligence Unit managing editor, Thought Leadership, Asia, Mr. Jesse Quigley Jones said "The cost of inaction: Secondary prevention of cardiovascular disease in Asia-Pacific" white paper found that despite the availability of effective interventions and proven care models for CVD, these were inconsistently implemented across the eight economies studied. "For instance, although each had policies for controlling CVD risk factors, such as obesity and tobacco use, few make explicit provision for preventing recurrent cardiovascular events. Furthermore, lack of government audits against quality care standards and poor compatibility of electronic health and medical records, makes it difficult to track the application of guidelines, referral to rehabilitation services, treatment adherence and outcomes."

"Healthcare systems that integrate patient-centric intervention, education and empowerment, such as electronic reminders and health records, may help to increase adherence, and subsequently improve overall patient outcomes," Mr Quigley Jones said.

Available for interview
– Ms Penny Wan, Amgen Regional Vice-President and General Manager, JAPAC, HONG KONG
– Jesse Quigley Jones, The Economist Intelligence Unit, Managing Editor, Thought Leadership, Asia, HONG KONG
– Dr. Chan Ngai-Yin, President, Hong Kong College of Cardiology, HONG KONG
– Dr Saikiran Leekha, Amgen Regional Medical Director, JAPAC, HONG KONG
– Prof. Carolyn Lam, Senior Consultant, National Heart Centre Singapore (NHCS), Professor of Duke-NUS Cardiovascular Academic Clinical Programme, SINGAPORE
– Mr Vernon Kang, Chief Executive Officer, Singapore Heart Foundation, SINGAPORE
– Edwin, 29, financial adviser & former hip-hop dancer who survived a heart attack last year, SINGAPORE

Media contacts:
Kirsten Bruce and Julia Slater, VIVA! Communications, AUSTRALIA
+61 401 717 566 / +61 422 074 354
kirstenbruce@vivacommunications.com.au / julia@vivacommunications.com.au

Eleanor Ng, Amgen, JAPAC, HONG KONG
+852 9469 3000 / eng03@amgen.com

About cardiovascular disease (CVD)
As the world's leading cause of premature death (10,17) CVD claims the lives of 26,000 people a day in Asia alone (18). In fact, Asia currently bears half the global CVD burden (19) as the world's fastest ageing region (20,21). The elderly are on track to cost the region* an estimated USD 20 trillion in healthcare expenses between 2015 and 2030 (20). Based on findings of the GBD Study 2016, ischemic heart disease and stroke are forecast to be the top two causes of early death in 2040, not only on a global basis, but also for the regions of East Asia and Southeast Asia. The rising incidence and CVD-related cost-of-illness will challenge the sustainability of health and financial systems worldwide. Therefore, health systems will need to apply primary and secondary prevention strategies to reduce healthcare costs, increase economic productivity, and improve quality of life.
* Includes the 14 economies of Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, the Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.

About the research
The Amgen-sponsored "The Cost of Inaction: Secondary prevention of cardiovascular disease in Asia-Pacific" is an Economist Intelligence Unit and EIU Healthcare report. The report describes the EIU Healthcare-created Secondary Prevention of Cardiovascular Disease in Asia-Pacific Scorecard findings, together with 11 in-depth interviews featuring global CVD experts. The scorecard was developed to assess the burden and health system response to secondary cardiovascular events in eight Asia-Pacific economies: Australia, China, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand. The report follows the 2018 EIU report, "The Cost of Silence: Cardiovascular disease in Asia", which examined the prevalence and costs arising from the top four modifiable risk factors that contribute to CVDs across the same eight economies.

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics, to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world, and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Forward-Looking Statements
This news release contains forward-looking statements based on the current expectations and beliefs of Amgen. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

References
1. Economist Intelligence Unit, "The cost of inaction: Secondary prevention of cardiovascular disease in Asia-Pacific" 2020. https://tinyurl.com/y8xwmu4w.
2. Secondary prevention and rehabilitation after coronary events or stroke: a review of monitoring issues. Australian Institute of Health and Welfare, Editor. 2003, AIHW Cat. No. CVD 25: Canberra.
3. American Heart Association. CDC Prevention Programs. 2018 February 2020; Available from: https://www.heart.org/en/get-involved/advocate/federal-priorities/ cdc-prevention-programs.
4. Chan, M.Y., et al., Acute coronary syndrome in the Asia-Pacific region. Int J Cardiol, 2016. 202: p. 861-9.
5. Poh, K.K., et al., Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: results from the Dyslipidemia International Study II. Eur J Prev Cardiol, 2018. 25(18): p. 1950-1963.
6. Mach, F., et al., 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020. 41(1): p. 111-188.
7. Kim, H.S., et al., Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Curr Med Res Opin, 2008. 24(7): p. 1951-63.
8. Park, J.E., et al., Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey. Eur J Prev Cardiol, 2012. 19(4): p. 781-94.
9. Bhatt, D.L., et al., Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis. JAMA, 2010. 304(12): p. 1350-1357.
10. G. B. D. Causes of Death Collaborators, Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, 2018. 392(10159): p. 1736-1788.
11. Notara, V., D.B. Panagiotakos, and C.E. Pitsavos, Secondary prevention of acute coronary syndrome. Socio-economic and lifestyle determinants: a literature review. Cent Eur J Public Health, 2014. 22(3): p. 175-82.
12. Deloitte Access Economics, The economic impact of stroke in Australia. 2013, National Stroke Foundation.
13. Harikrishnan, S., et al., A race against time: The Challenge of Cardiovascular Diseases in Developing Economies. Centre for Chronic Disease Control, 2014.
14. Yusuf, S., et al., Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med, 2014. 371(9): p. 818-27.
15. Piepoli, M.F., et al., Challenges in secondary prevention after acute myocardial infarction: A call for action. Eur J Prev Cardiol, 2016. 23(18): p. 1994-2006.
16. Briffa, T.G., et al., An integrated and coordinated approach to preventing recurrent coronary heart disease events in Australia. 2009. 190(12): p. 683-686.
17. Institute for Health Metrics and Evaluation (IHME), Findings from the Global Burden of Disease Study 2017. 2018: Seattle.
18. Roth, G.A., et al., Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol, 2017. 70(1): p. 1-25.
19. Ohira, T. and H. Iso, Cardiovascular disease epidemiology in Asia: an overview. Circ J, 2013. 77(7): p. 1646-52.
20. Asia Pacific Risk Centre, Advancing into the Golden Years: Cost of Healthcare for Asia Pacific's Elderly. 2016.
21. Deloitte, Voice of Asia. 2017: p. 25.


Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com